1. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
   Marina Ferreira Candido et al, 2023, Pharmaceutics CrossRef
2. Recent developments of 2-aminothiazoles in medicinal chemistry
   Debasis Das et al, 2016, European Journal of Medicinal Chemistry CrossRef
3. Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
   Elise Aasebø et al, 2020, Cancers CrossRef
4. The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells
   Chang-Jiang Hu et al, 2015, Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms CrossRef
5. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
   Jing Zhang et al, 2019, Molecular Cancer CrossRef
6. Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells
   Liling Jiang et al, 2022, Cancer Biology & Therapy CrossRef
7. Targeting cyclin-dependent kinase 9 in cancer therapy
   Yi-li Shen et al, 2022, Acta Pharmacologica Sinica CrossRef
8. Synergistic antitumor effects of CDK inhibitor SNS-032 and an oncolytic adenovirus co-expressing TRAIL and Smac in pancreatic cancer
   Yun Ge et al, 2017, Molecular Medicine Reports CrossRef
9. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery
   Ryan D. Martin et al, 2020, International Journal of Molecular Sciences CrossRef
10. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition ofMYBandMCL-1expression
    Partha Mitra et al, 2016, Oncotarget CrossRef
11. Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling
    GUI’E XIE et al, 2015, Oncology Reports CrossRef
12. Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death
    Xiaoou Xu et al, 2020, Molecular Cancer Therapeutics CrossRef
13. How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?
    Petr Lapcik et al, 2020, Cancers CrossRef
14. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma
    Samantha M. Guhan et al, 2021, Journal of Investigative Dermatology CrossRef
15. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
    María del Mar Noblejas-López et al, 2022, International Journal of Molecular Sciences CrossRef
16. Ethyl acetate fraction in ethanol extract from root of “Dai-Bai-Jie” (Marsdenia tenacissima): anti-tumor activity in A549 cancer cells
    Li Xiaohua et al, 2018, Journal of Traditional Chinese Medicine CrossRef
17. Targeting bromodomain and extraterminal proteins in breast cancer
    Jennifer M. Sahni et al, 2018, Pharmacological Research CrossRef
18. Getting under the skin: The role of CDK4/6 in melanomas
    Linghong Guo et al, 2020, European Journal of Medicinal Chemistry CrossRef
19. A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II—Biological functions and inhibitors
    Jianru Zhang et al, 2020, Bioorganic Chemistry CrossRef
20. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells
    Jaya Padmanabhan et al, 2021, Cancers CrossRef
21. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
    Anthony Cheung et al, 2022, Cancers CrossRef
22. Withdrawn: Cyclic Dependent Kinases (CDKs) in Cancer Pathogenesis and Therapeutics
    Bekesho Geleta et al, 2016, International Journal of Cancer Research CrossRef
23. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
    Shao Xie et al, 2016, Acta Pharmacologica Sinica CrossRef
24. Targeting CDK9: a promising therapeutic opportunity in prostate cancer
    Muhammed H Rahaman et al, 2016, Endocrine-Related Cancer CrossRef
25. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
    J D Leverson et al, 2015, Cell Death & Disease CrossRef